Anticoagulant reversal: the $64,000 question

Pathology Clinical Conference

Wednesday, February 5, 2020 at 12:00 PM

This grand round has already taken place.

Pathology level 2 conference room - Stony Brook, NY
February 5th, 2020
1.00 AMA PRA Category 1 Credit Hours


this discussion will cover DOAC ,  clinical practice guidelines, risks, benefits and effectiveness of  reversal agents and PCC

Dates and Times

Start: 2/5/2020 12:00 PM
End: 2/5/2020 1:00 PM


1.Recognize apixaban (Eliquis®), betrixaban (Bevyxxa®), dabigatran
(Pradaxa®), edoxaban (Savaysa®), and rivaroxaban (Xarelto®) as

2.Be aware of practice guidelines for reversal of DOACs and management of bleeding events

3.Describe risks, benefits and cost effectiveness of antidotes and prothrombin complex concentrates


  • Dr. Lisa Senzel
    • Anticoagulant reversal: the $64,000 question


Pathology level 2 conference room
100 Nicolls rd
university hospital room 749
Stony Brook, NY 11794


The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) . Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Give us a call
(631) 444-2094
Office of Continuing Medical Education
Renaissance School of Medicine at Stony Brook University
HSC, Level 2, Room 142
Stony Brook, New York 11794-8222